IP Library Granted Patent US 10,799,539
Granted Patent B2
US 10,799,539 · App. 15/965,090 · Granted Oct 13, 2020

Microbiota restoration therapy (MRT) compositions and methods of manufacture

Inventors: Lee A. Jones (Fridley, MN); Courtney R. Jones (Fridley, MN); Beth Anne-Szkudlarek Brown (Plymouth, MN); Joshua Erickson (Champlin, MN)
Assignee: REBIOTIX, INC.
A61K35/74A61K9/0053A61K9/1623A61K9/1641A61K9/1694A61K9/19A61K9/4808A61K9/4816A61K9/4833A61K9/4858A61K9/4866A61K9/4875A61K35/38A61P1/14A61K47/10A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,799,539
App. No.
15/965,090
Granted
Oct 13, 2020
Kind
B2
Abstract

Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Claims (40)

1. A method for manufacturing a microbiota restoration therapy composition, the method comprising:

collecting a fecal sample from a donor;

processing the fecal sample to form a processed fecal sample;

centrifuging the processed fecal sample to form a purified intermediate;

mixing the purified intermediate with a lyophilization excipient to form a lyophilization intermediate;

wherein the lyophilization excipient includes polyethylene glycol, trehalose, sucrose, and glycerin; and

lyophilizing the lyophilization intermediate.

2. The method of claim 1 , wherein centrifuging the processed fecal sample to form a purified intermediate includes a low speed centrifugation.

3. The method of claim 1 , wherein centrifuging the processed fecal sample to form a purified intermediate includes centrifuging the processed fecal sample at a low speed, removing the supernatant, and centrifuging the supernatant at a high speed.

4. The method of claim 3 , wherein centrifuging the supernatant at a high speed includes centrifuging at a speed sufficient to create a centrifugal force in the range of about 8-12,000 g.

5. The method of claim 3 , wherein centrifuging the supernatant at a high speed includes centrifuging at a speed sufficient to create a centrifugal force of about 10,000 g.

6. The method of claim 3 , wherein centrifuging the processed fecal sample at a low speed includes centrifuging at a speed sufficient to create a centrifugal force of about 300 g.

7. The method of claim 1 , wherein the lyophilization excipient includes about 0.5-20% polyethylene glycol.

8. The method of claim 1 , wherein the lyophilization excipient includes about 10% trehalose.

9. The method of claim 1 , wherein the lyophilization excipient includes about 10% sucrose.

10. The method of claim 1 , wherein the lyophilization excipient includes about 0.1-5% glycerol.

11. The method of claim 1 , wherein lyophilizing the lyophilization intermediate forms a lyophilized pellet, and further comprising processing the lyophilized pellet, encapsulating the lyophilized pellet, or both.

12. A method for manufacturing a microbiota restoration therapy composition, the method comprising:

processing a fresh fecal sample to form a processed fecal sample;

centrifuging the processed fecal sample to form a purified intermediate, wherein centrifuging includes a first centrifugation process and a second centrifugation process;

mixing the purified intermediate with a lyophilization excipient to form a lyophilization intermediate;

wherein the lyophilization excipient includes polyethylene glycol;

wherein the lyophilization excipient includes trehalose, sucrose, or both; and

lyophilizing the lyophilization intermediate.

13. The method of claim 12 , wherein the first centrifugation process forms a first pellet and a supernatant and wherein the second centrifugation process includes centrifuging the supernatant.

14. The method of claim 12 , wherein the second centrifugation process includes centrifuging at a speed sufficient to create a centrifugal force in the range of about 8-12,000 g.

15. The method of claim 12 , wherein the lyophilization excipient includes glycerol.

16. The method of claim 12 , wherein the lyophilization excipient includes trehalose, sucrose, and glycerin.

17. The method of claim 12 , wherein lyophilizing the lyophilization intermediate forms a lyophilized pellet, and further comprising grinding the lyophilized pellet to form a ground pellet.

18. The method of claim 17 , further comprising encapsulating the ground pellet.

19. An oral microbiota restoration therapy composition, comprising:

a lyophilized fecal preparation, the lyophilized fecal preparation being formed by:

collecting a fecal sample from a donor,

processing the fecal sample to form a processed fecal sample,

centrifuging the processed fecal sample to form a purified intermediate,

mixing the purified intermediate with a lyophilization excipient to form a lyophilization intermediate,

wherein the lyophilization excipient includes polyethylene glycol, trehalose, sucrose, and glycerin, and

lyophilizing the lyophilization intermediate; and

a capsule containing the lyophilized fecal preparation.

20. The oral microbiota restoration therapy composition of claim 19 , wherein the capsule includes hypromellose.

Assignments (2)
CHANGE OF NAME Recorded Jan 27, 2025
From: REBIOTIX INC.
To: FERRING MICROBIOME INC.
Reel/Frame 070022/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2023
From: JONES, LEE A.; JONES, COURTNEY R.; BROWN, BETH ANNE-SZKUDLAREK; ERICKSON, JOSHUA
To: REBIOTIX, INC.
Reel/Frame 062803/0233 →
Continuity (4)
Continuation 15178176 · Jun 9, 2016
Provisional Application 62173182 · Jun 9, 2015
Provisional Application 62247825 · Oct 29, 2015
Related Publication 20180243349A1 · Aug 30, 2018
Cited By (1)
US 12,303,537